粒细胞-单核细胞集落刺激因子增强淋巴细胞和单核细胞在抗体依赖性细胞毒性中的细胞毒能力。
Granulocyte-monocyte-colony-stimulating factor augments the cytotoxic capacity of lymphocytes and monocytes in antibody-dependent cellular cytotoxicity.
作者信息
Masucci G, Wersäll P, Ragnhammar P, Mellstedt H
机构信息
Department of Oncology (Radiumhemmet), Karolinska Hospital, Stockholm, Sweden.
出版信息
Cancer Immunol Immunother. 1989;29(4):288-92. doi: 10.1007/BF00199217.
Abstract
Human peripheral blood mononuclear cells (lymphocytes and monocytes) were preincubated for 0-24 h with human recombinant granulocyte-monocyte-colony-stimulating factor (GM-CSF) and used as effector cells in an 18 h antibody-dependent cellular cytotoxicity (ADCC) assay with SW948 (a human colorectal carcinoma cell line) as target cells and mAb 17-1A. A significant increase in the lytic capability was noted after 0.5-2 h of preactivation while longer preincubation times did not significantly increase the lytic potential. GM-CSF at 0.01 microgram/ml induced the best tumor cell lysis while higher concentrations were inhibitory. GM-CSF pretreatment induced a statistically significant increase in the lytic capacity of both monocytes and lymphocytes in ADCC as well as in the spontaneous cytotoxicity.
摘要
人外周血单核细胞（淋巴细胞和单核细胞）与人重组粒细胞-单核细胞集落刺激因子（GM-CSF）预孵育0至24小时，然后用作效应细胞，以SW948（一种人结肠癌细胞系）为靶细胞，mAb 17-1A进行18小时的抗体依赖性细胞毒性（ADCC）测定。预激活0.5至2小时后，裂解能力显著增加，而更长的预孵育时间并未显著增加裂解潜力。0.01微克/毫升的GM-CSF诱导最佳的肿瘤细胞裂解，而更高浓度则具有抑制作用。GM-CSF预处理在ADCC以及自发细胞毒性中均诱导单核细胞和淋巴细胞的裂解能力出现统计学上的显著增加。
相似文献
1
Granulocyte-monocyte-colony-stimulating factor augments the cytotoxic capacity of lymphocytes and monocytes in antibody-dependent cellular cytotoxicity.
Cancer Immunol Immunother. 1989;29(4):288-92. doi: 10.1007/BF00199217.
2
Granulocyte-monocyte colony-stimulating-factor augments the interleukin-2-induced cytotoxic activity of human lymphocytes in the absence and presence of mouse or chimeric monoclonal antibodies (mAb 17-1A).
Cancer Immunol Immunother. 1990;31(4):231-5. doi: 10.1007/BF01789174.
3
4
Cytotoxic functions of blood mononuclear cells in patients with colorectal carcinoma treated with mAb 17-1A and granulocyte/macrophage-colony-stimulating factor.
Cancer Immunol Immunother. 1992;35(3):158-64. doi: 10.1007/BF01756182.
5
Interleukin-4 augments the cytotoxic capacity of lymphocytes and monocytes in antibody-dependent cellular cytotoxicity.
Cancer Immunol Immunother. 1991;33(1):45-9. doi: 10.1007/BF01742527.
6
Prestimulation of monocytes by the cytokines GM-CSF or IL-2 enhances the antibody dependent cellular cytotoxicity of monoclonal antibody 17-1A.
Z Gastroenterol. 2000 Aug;38(8):615-22. doi: 10.1055/s-2000-7511.
7
GM-CSF enhances 3F8 monoclonal antibody-dependent cellular cytotoxicity against human melanoma and neuroblastoma.
Blood. 1989 May 15;73(7):1936-41.
8
Cytotoxicity of white blood cells activated by granulocyte-colony-stimulating factor, granulocyte/macrophage-colony-stimulating factor and macrophage-colony-stimulating factor against tumor cells in the presence of various monoclonal antibodies.
Cancer Immunol Immunother. 1994 Oct;39(4):254-62. doi: 10.1007/BF01525989.
9
Macrophage colony-stimulating factor enhances monocyte and macrophage antibody-dependent cell-mediated cytotoxicity.
Cell Immunol. 1989 Mar;119(1):182-92. doi: 10.1016/0008-8749(89)90234-7.
10
Colony-stimulating factor enhancement of myeloid effector cell cytotoxicity towards neuroectodermal tumour cells.
Br J Haematol. 1993 Apr;83(4):545-53. doi: 10.1111/j.1365-2141.1993.tb04689.x.
引用本文的文献
1
Exploiting Gangliosides for the Therapy of Ewing's Sarcoma and H3K27M-Mutant Diffuse Midline Glioma.
Cancers (Basel). 2021 Jan 29;13(3):520. doi: 10.3390/cancers13030520.
2
Recombinant Granulocyte-Macrophage Colony-Stimulating Factor (rGM-CSF) : A Review of its Pharmacological Properties and Prospective Role in the Management of Myelosuppression.
Drugs. 1992 Apr;43(4):516-560. doi: 10.2165/00003495-199243040-00008.
3
Combination strategies to enhance antitumor ADCC.
Immunotherapy. 2012 May;4(5):511-27. doi: 10.2217/imt.12.38.
4
Influence of varying doses of granulocyte-macrophage colony-stimulating factor on pharmacokinetics and antibody-dependent cellular cytotoxicity.
Cancer Immunol Immunother. 2008 Mar;57(3):379-88. doi: 10.1007/s00262-007-0377-1. Epub 2007 Aug 4.
5
New paradigms for therapy for osteosarcoma.
Curr Oncol Rep. 2005 Nov;7(6):410-4. doi: 10.1007/s11912-005-0005-1.
6
7
Influence of cytokines, monoclonal antibodies and chemotherapeutic drugs on epithelial cell adhesion molecule (EpCAM) and LewisY antigen expression.
Clin Exp Immunol. 2001 Jan;123(1):9-14. doi: 10.1046/j.1365-2249.2001.01435.x.
8
Anti-tumoral effect of GM-CSF with or without cytokines and monoclonal antibodies in solid tumors.
Med Oncol. 1996 Sep;13(3):167-76. doi: 10.1007/BF02990844.
9
Neutralising antibodies to granulocyte-macrophage colony stimulating factor (GM-CSF) in carcinoma patients following GM-CSF combination therapy.
Med Oncol. 1996 Sep;13(3):161-6. doi: 10.1007/BF02990843.
10
Granulocyte-macrophage colony-stimulating factor and the immune system.
Med Oncol. 1996 Sep;13(3):133-40. doi: 10.1007/BF02990841.
本文引用的文献
1
Interleukin 1 and T-cell activation.
Immunol Today. 1987;8(11):330-2. doi: 10.1016/0167-5699(87)90006-5.
2
Blood and lymph node T-lymphocyte subsets in non-Hodgkin lymphomas.
Scand J Haematol. 1983 Jan;30(1):68-78. doi: 10.1111/j.1600-0609.1983.tb00636.x.
3
Tumors undergoing rejection induced by monoclonal antibodies of the IgG2a isotype contain increased numbers of macrophages activated for a distinctive form of antibody-dependent cytolysis.
Proc Natl Acad Sci U S A. 1984 Jun;81(11):3506-10. doi: 10.1073/pnas.81.11.3506.
4
Isolation of human blood monocytes with Nycodenz, a new non-ionic iodinated gradient medium.
Scand J Immunol. 1983 May;17(5):429-36. doi: 10.1111/j.1365-3083.1983.tb00809.x.
5
Purified human granulocyte-macrophage colony-stimulating factor: direct action on neutrophils.
Science. 1984 Dec 14;226(4680):1339-42. doi: 10.1126/science.6390681.
6
Quantitative studies on phytohaemagglutinin-induced cytotoxicity by human lymphocytes against homologous cells in tissue culture.
Immunology. 1967 May;12(5):525-36.
7
Differential effects of human granulocytes and lymphocytes on human fibroblasts in vitro.
Clin Exp Immunol. 1968 Oct;3(8):817-36.
8
In vitro studies of lymphocytes from patients with plasma cell myeloma. I. Stimulation by mitogens and cytotoxic activities.
Clin Exp Immunol. 1973 Nov;15(3):309-20.
9
A one-stage procedure for isolation of granulocytes and lymphocytes from human blood. General sedimentation properties of white blood cells in a 1g gravity field.
Scand J Clin Lab Invest Suppl. 1968;97:51-76.
10
Eradication of established human melanoma tumors in nude mice by antibody-directed effector cells.
J Exp Med. 1985 Jun 1;161(6):1315-25. doi: 10.1084/jem.161.6.1315.
Zotero 插件